pH-sensitive anti-CTLA4 antibodies: yes to efficacy, no to toxicity
For a long time,anti-CTLA-4 antibodies were believed to mediate their beneficial cancer immunotherapeutic effect (CITE),whose effectiveness and safety are limited by associated immune-related adverse effects (irAE),via blocking the interaction between CTLA-4 and its ligands,a mechanism known as checkpoint blockade.Using novel engineered antibodies,Zhang et al.challenge this paradigm in the present study,demonstrating that the irAE of anti-CTLA-4 antibodies can be uncoupled from their CITE,raising hopes for the design of a new generation of safer and more effective anti-CTLA-4 antibodies.
29
2019-09-09（万方平台首次上网日期，不代表论文的发表时间）
共2页
601-602
